PACCALET Alexandre
- Position: Post-doctorant
- Mail : alexandre.paccalet@chu-lyon.fr
Team member :
Find this member on networks :
About
Alexandre is a cardiovascular immunometabolism researcher with deep expertise in inflammation and immune regulation.
He completed his PhD in Lyon under the mentorship of Pr Ovize, followed by a postdoctoral fellowship at Harvard Medical School in Pr Nahrendorf’s lab.
Supported by a prestigious Marie Skłodowska-Curie fellowship, he developed his research project at the CarMeN lab (UMR1060) and Hospices Civils de Lyon.
In 2026, Alexandre will launch his independent research group, thanks to the ATIP Avenir award.
His lab investigates how monocyte metabolism drives the progression of cardiovascular diseases, intending to uncover novel therapeutic strategies.
Outside the lab, Alexandre enjoys spending time with family and friends, cycling through scenic routes, and hiking.
5 major publications:
Deleterious anti-inflammatory macrophage recruitment in early post-infarction phase: unravelling the IL-6/MCP-1/STAT3 axis
Alexandre Paccalet, et al. Journal of American College of Cardiology : Basic to translational science. 2024 doi/ 10.1016/j.jacbts.2024.01.019
Bone marrow adipocytes fuel emergency hematopoiesis after myocardial infarction
Shuang Zhang*, Alexandre Paccalet*, et al. Nature Cardiovascular Research. 2023 doi: 10.1038/s44161-023-00388-7
The role of stromal and immune cells in atrial disease
Maarten Hulsmans, Maximilian J. Schloss, I-Hsiu Lee, Aneesh Bapat, Claudio Vinegoni, Alexandre Paccalet, et al. Science. 2023 doi: 10.1126/science.abq3061
Cerebrospinal fluid can exit into the skull bone marrow and instruct cranial hematopoiesis in mice with bacterial meningitis
Fadi Pulopus*, Jean Cruz-Hernández, Chongbo Yang, Zeynep Kaya, Alexandre Paccalet, et al. Nature Neuroscience 2022 doi: 10.1038/s41593-022-01060-2
Serum soluble Tumor Necrosis Factor Receptor (sTNFR) 1 and 2 are early prognosis markers after STEMI
Alexandre Paccalet, et al. Frontiers in pharmacology. 2021 doi: 10.3389/fphar.2021.656928
